Michael S Seaman

List of Publications by Year
in descending order

187 papers	27,674 citations	9756 73 h-index	6454 157 g-index
200 all docs	200 docs citations	200 times ranked	20515 citing authors

#	Article	IF	Citations
1	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	13.7	2,112
2	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	6.0	1,600
3	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 2020, 383, 2291-2293.	13.9	1,069
4	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, 2011, 333, 1633-1637.	6.0	1,046
5	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009, 458, 636-640.	13.7	806
6	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491.	13.7	665
7	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature, 2013, 503, 224-228.	13.7	593
8	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. Journal of Virology, 2010, 84, 1439-1452.	1.5	589
9	Complex-type <i>N</i> -glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3268-77.	3.3	505
10	HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015, 349, aac4223.	6.0	482
11	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	13.5	478
12	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	13.7	463
13	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 2012, 482, 89-93.	13.7	452
14	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. Journal of Immunological Methods, 2014, 409, 131-146.	0.6	435
15	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature, 2013, 503, 277-280.	13.7	424
16	Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for InÂVivo Activity. Cell, 2014, 158, 1243-1253.	13.5	419
17	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 2016, 535, 556-560.	13.7	400
18	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191.	15.2	399

#	Article	IF	Citations
19	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	13.7	393
20	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	1.5	393
21	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	13.7	392
22	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science, 2011, 334, 1289-1293.	6.0	345
23	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	6.6	342
24	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell, 2014, 158, 989-999.	13.5	337
25	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell, 2013, 155, 531-539.	13.5	334
26	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids, 2014, 28, 163-169.	1.0	334
27	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	3.3	324
28	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Network Open, 2020, 3, e2030455.	2.8	315
29	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	6.6	304
30	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science, 2015, 349, 320-324.	6.0	303
31	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	1.5	274
32	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519, 87-91.	13.7	265
33	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 2016, 352, 997-1001.	6.0	263
34	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	3.8	260
35	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	3.3	247
36	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	6.0	246

#	ARTICLE	IF	CITATIONS
37	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	13.7	244
38	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	13.5	239
39	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science, 2021, 373, 642-648.	6.0	211
40	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. Cell Reports, 2014, 7, 785-795.	2.9	199
41	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	15.2	195
42	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature Structural and Molecular Biology, 2016, 23, 906-915.	3.6	188
43	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, 2020, 183, 1496-1507.e16.	13.5	182
44	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine, 2011, 3, 81ra36.	5.8	179
45	Structural basis for membrane anchoring of HIV-1 envelope spike. Science, 2016, 353, 172-175.	6.0	169
46	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nature Communications, 2016, 7, 10618.	5.8	166
47	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet, The, 2018, 391, 563-571.	6.3	165
48	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7908-E7916.	3.3	164
49	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Science Translational Medicine, 2014, 6, 236ra63.	5.8	160
50	Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell, 2016, 165, 1621-1631.	13.5	157
51	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	4.2	156
52	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	2.1	150
53	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	13.7	145
54	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Science Translational Medicine, 2018, 10, .	5.8	133

#	Article	IF	Citations
55	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell, 2016, 165, 1609-1620.	13.5	130
56	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	5.8	128
57	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	5.1	124
58	Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. Journal of Virology, 2005, 79, 2956-2963.	1.5	120
59	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	5.6	119
60	Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science, 2015, 349, 191-195.	6.0	113
61	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection InÂVivo. Cell, 2017, 170, 637-648.e10.	13.5	111
62	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	3.6	110
63	Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell, 2015, 160, 433-446.	13.5	109
64	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106
65	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	13.5	106
66	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Reports, 2022, 39, 110729.	2.9	102
67	Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses. PLoS ONE, 2011, 6, e24078.	1.1	99
68	A single injection of crystallizable fragment domainâ€“modified antibodies elicits durable protection from SHIV infection. Nature Medicine, 2018, 24, 610-616.	15.2	94
69	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15.	13.5	94
70	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. Journal of Experimental Medicine, 2012, 209, 1091-1103.	4.2	91
71	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports, 2018, 25, 893-908.e7.	2.9	91
72	Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs. Journal of Virology, 2010, 84, 3270-3279.	1.5	89

#	Article	IF	Citations
73	Neutralization tiers of HIV-1. Current Opinion in HIV and AIDS, 2018, 13, 128-136.	1.5	89
74	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	5.8	87
75	Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Medicinal Chemistry Letters, 2016, 7, 330-334.	1.3	86
76	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	6.6	85
77	Relationship between latent and rebound viruses in a clinical trial of antiâ€“HIV-1 antibody 3BNC117. Journal of Experimental Medicine, 2018, 215, 2311-2324.	4.2	84
78	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	2.1	81
79	Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses. Cell, 2018, 173, 1783-1795.e14.	13.5	80
80	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. Journal of Experimental Medicine, 2019, 216, 1301-1310.	4.2	80
81	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	4.2	79
82	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Computational Biology, 2010, 6, e1000955.	1.5	78
83	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	2.1	78
84	A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15859-15864.	3.3	75
85	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	1.5	75
86	Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606, 368-374.	13.7	75
87	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13540-13545.	3.3	73
88	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	13.5	73
89	Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8892-E8899.	3.3	72
90	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. Journal of Virology, 2012, 86, 3393-3397.	1.5	71

#	Article	IF	Citations
91	Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. Journal of Virology, 2016, 90, 636-649.	1.5	70
92	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	2.1	68
93	Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022, 606, 375-381.	13.7	65
94	Induction of HIV-1â€"Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. Journal of Infectious Diseases, 2015, 211, 518-528.	1.9	60
95	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 2019, 14, e0219142.	1.1	58
96	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host and Microbe, 2019, 26, 623-637.e8.	5.1	56
97	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. ELife, 2017, 6, .	2.8	52
98	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9981-9990.	3.3	51
99	Subsets of Memory Cytotoxic T Lymphocytes Elicited by Vaccination Influence the Efficiency of Secondary Expansion In Vivo. Journal of Virology, 2004, 78, 206-215.	1.5	50
100	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. PLoS Pathogens, 2020, 16, e1008083.	2.1	50
101	Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein. Nature Communications, 2020, 11, 2317.	5.8	49
102	Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Cell Reports, 2018, 23, 2568-2581.	2.9	46
103	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022, 28, 1288-1296.	15.2	44
104	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	2.1	43
105	Broadly Neutralizing Antibodies for HIV-1 Prevention. Frontiers in Immunology, 2021, 12, 712122.	2.2	43
106	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. Journal of Virology, 2015, 89, 2507-2519.	1.5	42
107	Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 473-483.	0.9	40
108	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	1.5	40

#	Article	IF	Citations
109	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	40
110	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. Journal of Virology, 2018, 92, .	1.5	39
111	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	15.2	39
112	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	2.1	38
113	Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology, 2007, 367, 175-186.	1.1	37
114	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. Clinical Infectious Diseases, 2017, 64, 1098-1104.	2.9	36
115	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 1061-1070.	4.6	36
116	Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax. Journal of Infectious Diseases, 2010, 201, 1353-1360.	1.9	35
117	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	1.5	35
118	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	1.9	35
119	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	5.8	35
120	Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1. PLoS Pathogens, 2014, 10, e1004552.	2.1	34
121	Disruption of Helix-Capping Residues 671 and 674 Reveals a Role in HIV-1 Entry for a Specialized Hinge Segment of the Membrane Proximal External Region of gp41. Journal of Molecular Biology, 2014, 426, 1095-1108.	2.0	34
122	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. Journal of Virology, 2021, 95, e0040421.	1.5	34
123	Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. Journal of Virology, 2014, 88, 6959-6969.	1.5	32
124	A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1. Journal of Biological Chemistry, 2014, 289, 29912-29926.	1.6	32
125	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	1.5	30
126	A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Molecular Immunology, 2015, 66, 364-374.	1.0	30

#	Article	IF	Citations
127	HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4 ⁺ T Cell Responses. Journal of Virology, 2016, 90, 2208-2220.	1.5	29
128	Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. Journal of Virology, 2015, 89, 1965-1974.	1.5	28
129	HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nature Chemical Biology, 2020, 16, 529-537.	3.9	28
130	Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys. Journal of Virology, 2005, 79, 4580-4588.	1.5	27
131	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine, 2014, 32, 2109-2116.	1.7	27
132	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	5.8	27
133	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. Journal of Virology, 2016, 90, 10362-10378.	1.5	26
134	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	1.5	26
135	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Cell Reports, 2019, 29, 3060-3072.e7.	2.9	26
136	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology, 2015, 475, 37-45.	1.1	25
137	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	1.5	25
138	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	13.5	25
139	Discovery of O-Linked Carbohydrate on HIV-1 Envelope and Its Role in Shielding against One Category of Broadly Neutralizing Antibodies. Cell Reports, 2020, 30, 1862-1869.e4.	2.9	25
140	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	2.3	25
141	Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. Journal of Virology, 2018, 92, .	1.5	24
142	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. Journal of Virology, 2017, 91, .	1.5	23
143	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	5.1	23
144	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	1.5	22

#	Article	IF	Citations
145	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Computational Biology, 2018, 14, e1006093.	1.5	19
146	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0 0 rgBT /Overlock 10	2.1	19
147	Î» Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. Journal of Infectious Diseases, 2016, 213, 156-164.	1.9	18
148	Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4477-4482.	3.3	18
149	Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. Journal of Pharmaceutical Sciences, 2018, 107, 3032-3046.	1.6	18
150	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. Journal of Virology, 2021, 95, .	1.5	18
151	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathogens, 2016, 12, e1005431.	2.1	18
152	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. ELife, 2021, 10, .	2.8	16
153	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight, 2018, 3, .	2.3	16
154	Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent <scp>d</scp> -peptide HIV entry inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22436-22442.	3.3	15
155	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. Nature Communications, 2020, 11, 3195.	5.8	15
156	Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, ofw100.	0.4	14
157	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine, 2017, 35, 1-9.	1.7	14
158	A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. Journal of Virology, 2019, 93, .	1.5	14
159	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	4.2	14
160	Transient CD4⁺T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses. Journal of Virology, 2016, 90, 4278-4288.	1.5	13
161	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	1.5	13
162	Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. Journal of Immunological Methods, 2020, 479, 112764.	0.6	13

#	Article	IF	Citations
163	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	5.8	11
164	Engineering panâ€“HIV-1 neutralization potency through multispecific antibody avidity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	11
165	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. Journal of Virology, 2015, 89, 9090-9102.	1.5	10
166	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. Journal of Virology, 2018, 92, .	1.5	10
167	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	2.8	10
168	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. Journal of Virology, 2018, 92, .	1.5	9
169	A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli. Applied Microbiology and Biotechnology, 2019, 103, 8875-8888.	1.7	9
170	Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. Journal of Pharmaceutical Sciences, 2020, 109, 233-246.	1.6	9
171	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. Journal of Immunological Methods, 2020, 479, 112736.	0.6	9
172	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. Cell Reports, 2021, 35, 109167.	2.9	8
173	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. Antibodies, 2020, 9, 36.	1.2	7
174	Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection. Journal of Clinical Investigation, 2020, 130, 6429-6442.	3.9	7
175	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. Aids, 2021, 35, 1567-1574.	1.0	6
176	Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys. Journal of Virology, 2014, 88, 13510-13515.	1.5	5
177	Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C. AIDS Research and Human Retroviruses, 2015, 31, 1192-1201.	0.5	5
178	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. Journal of Virology, 2020, 94, .	1.5	5
179	Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. Vaccine, 2020, 38, 3436-3446.	1.7	5
180	Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. Journal of Virology, 2021, 95, .	1.5	3

#	Article	IF	Citations
181	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	2.1	2
182	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. Npj Vaccines, 2021, 6, 126.	2.9	2
183	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infectious Diseases, 2021, 8, ofaa606.	0.4	2
184	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. Npj Vaccines, 2022, 7, 2.	2.9	2
185	Tâ€cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. Immunology, 2018, 155, 458-466.	2.0	1
186	Investigating Broad Neutralization in HIV-1 Non-B Subtype Infection in YaoundÃ©, Cameroon. AIDS Research and Human Retroviruses, 2014, 30, A152-A152.	0.5	0
187	Topology Influences V2 Epitope Focusing. AIDS Research and Human Retroviruses, 2014, 30, A193-A193.	0.5	0